Bloomberg journalists discuss today's biggest winners and losers in the stock market. Listen for analysis on the companies ...

Eli Lilly will acquire gene-editing startup Verve Therapeutics for up to US$1.3 billion to boost its pipeline beyond its blockbuster weight-loss and diabetes drugs.

Verve Therapeutics stock nearly doubled Tuesday after Eli Lilly agreed to buy the gene-editing company for up to $1.3 billion ...

In today's Pharmalittle roundup, we're reading about a Lilly deal, a gene therapy shock for Duchenne families, and more.

U.S. stock index futures on Tuesday slipped, as market participants remained on edge amid Israel and Iran's conflict. Here ...

Top oil chief executives have raised the alarm over Israel and Iran’s escalating... Turnover at the Irish arm of the telecommunication company Nokia dropped almost 10... The head of Renault’s budget ...

If finalized, the deal, which was also signed on to by the District of Columbia and U.S. territories, would pay out over the next 15 years. Also: Eli Lilly's experimental weight loss drug, a new Lupus ...

Eli Lilly has confirmed plans for a $1.3 billion takeover bid for Verve Therapeutics, upgrading a collaboration between the ...